San Diego-centered Viking Therapeutics marked by itself as a significant competitor while in the weight loss drug market in February just after revealing promising data from the mid-stage demo of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when offered for a weekly injection As well as in March the